ImmunityBio’s Anktiva Sales Double, but a $633 Million Loss and FDA Warning Cloud the Picture

ImmunityBio has posted a blistering 168% year-over-year jump in first-quarter product revenue, driven entirely by its bladder cancer drug Anktiva. But the headline numbers tell only half the story: a GAAP net loss of $632.8 million and a recent FDA warning letter have left investors parsing the fine print.

Net product revenue for the three months ended March 2026 reached $44.2 million, up from $16.5 million in the same period last year and 15% higher than the fourth quarter of 2025. The company’s full-year 2025 revenue of $113 million — seven times the 2024 figure — provides context for the current trajectory. If the quarterly pace holds, ImmunityBio should easily surpass that mark in 2026.

Yet the bottom line is jarring. The $632.8 million GAAP net loss is largely a paper phenomenon: $530.9 million came from non-cash fair-value adjustments tied to warrants, derivatives, and a related-party convertible note, plus the write-down of a convertible note receivable. The adjusted net loss of $86.2 million offers a clearer view of operating performance. Cash and marketable securities stood at $380.9 million at quarter-end, up from $242.8 million in December 2025.

Global Expansion Accelerates

Anktiva is now approved in five regulatory jurisdictions covering roughly 34 countries. The latest addition is Macau — the drug’s first authorization in Asia. In the Middle East and North Africa, distribution began within two months of signing a partnership with Biopharma and Cigalah Healthcare.

Should investors sell immediately? Or is it worth buying ImmunityBio?

On the clinical front, the pivotal QUILT-2.005 study in BCG-naïve non-muscle invasive bladder cancer (NMIBC) patients has completed enrollment. An independent data monitoring committee confirmed no additional patients are needed. ImmunityBio plans to file a supplemental Biologics License Application (sBLA) with the FDA in 2026.

The National Comprehensive Cancer Network (NCCN) has also updated its guidelines. Anktiva plus BCG now carries a Category 2A recommendation for patients with papillary disease without carcinoma in situ, adding to the existing recommendation for CIS patients.

Regulatory and Legal Headwinds

The revenue momentum, however, is colliding with serious regulatory friction. The FDA issued a warning letter in the spring over past promotional materials for Anktiva. Management says corrective actions are underway but has provided few specifics. Adding to the pressure, a securities class action has been filed, also centered on historical marketing practices. The lead plaintiff deadline falls at the end of May 2026.

ImmunityBio at a turning point? This analysis reveals what investors need to know now.

The commercial expansion is real and accelerating. Whether the regulatory and legal distractions will slow it down should become clearer later this year, when the sBLA submission date arrives and the class-action litigation begins to take shape.

Ad

ImmunityBio Stock: New Analysis - 8 May

Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated ImmunityBio analysis...

en | US45256X1037 | IMMUNITYBIO’S | boerse | 69294736 |